Martin D. Madaus - 20 Oct 2023 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Reporting relationship: Director
Issuer ticker: LAB
Reported as of: 20 Oct 2023
Net transaction value: +$3,998
SEC form: 4
Accepted by SEC: 20 Oct 2023, 21:30:07 UTC
Prior SEC filing: 16 Jun 2023
Next SEC filing: 04 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Martin D. Madaus by Agnieszka Gallagher, Attoney-in-Fact

Key filing fact

Martin D. Madaus filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 20 Oct 2023.

Key facts

This page summarizes Martin D. Madaus's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Oct 2023, 21:30.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: +$3,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LAB transaction

Common Stock

Award

Transaction value: $3,998
Shares: +1,574
Change %: +1.5%
Price: $2.54
Shares after: 104,111
Date: 20 Oct 2023
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control.

Footnote F2

The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board.

Footnote F3

Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above.